Relmada Therapeutics, Inc. (RLMD)

Market Cap	20.25M
Revenue (ttm)	n/a
Net Income (ttm)	-75.71M
Shares Out	33.19M
EPS (ttm)	-2.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	151,512
Open	0.6100
Previous Close	0.6102
Day's Range	0.6095 - 0.6754
52-Week Range	0.2404 - 4.4700
Beta	0.60
Analysts	Buy
Price Target	5.00 (+719.54%)
Earnings Date	Aug 6, 2025

About RLMD

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: RLMD
• Website: https://www.relmada.com

Analyst Summary

According to 3 analysts, the average rating for RLMD stock is "Buy." The 12-month stock price target is $5.0, which is an increase of 719.54% from the latest price.

Price Target

$5.0

(719.54% upside)

Analyst Consensus: Buy